Castle Biosciences reported a 24% revenue increase in Q3 2026 to $102.9 million, fueled by a 47% rise in TissueCypher test volumes. The company raised its full-year 2026 revenue guidance to $385-395 million from $365-375 million, reflecting strong portfolio performance and operational efficiency. Despite a net loss of $4.1 million in Q3, adjusted EBITDA improved to $12.7 million. Castle Biosciences expects to achieve positive adjusted EBITDA for Q4 2026 and beyond, supported by ongoing growth in dermatologic and gastroenterological test offerings.
Castle Biosciences reported a 24% revenue increase in Q3 2026. For readers following the Health sector, here is Pluang's market snapshot as of Nov 06, 2026 04:11 WIB: out of 150 priced US Health stocks, 16 rose and 134 fell. Notable movers include XRAY at USD 8.82 with a 17.18% decline, TXG at USD 56.99 with 88% sell order activity, and TWST at USD 120.79 with 96% sell order activity.
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
A dormant Bitcoin wallet holding 8.18 BTC originally worth about $470 is now valued at approximately $660,000. Zhao Changpeng commented that Bitcoin is not just a store of value but continues to appreciate over time. This highlights Bitcoin's potenti...
